Company Overview

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on immuno-oncology. The company applies proprietary computational biology and predictive discovery platforms to identify novel immune checkpoint regulators and drug targets, primarily for cancer treatment. Compugen operates at the intersection of biotechnology, drug discovery, and artificial intelligence–driven biology, with its core value proposition centered on uncovering previously unknown biological mechanisms that can be translated into first-in-class therapeutics.

Founded in 1993, Compugen initially focused on computational genomics before strategically pivoting in the mid-2000s toward immunology and oncology as these fields matured. The company’s evolution has been marked by the development of internally discovered immune targets and advancement into clinical-stage programs. Compugen is publicly traded on NASDAQ under the ticker CGEN and has positioned itself as a discovery-driven partner to larger pharmaceutical companies.

Business Operations

Compugen’s operations are organized around a single integrated business model that encompasses computational target discovery, biological validation, and clinical development. The company generates value primarily through the advancement of proprietary drug candidates and through strategic collaborations that include upfront payments, research funding, milestone payments, and potential royalties. Its pipeline is focused on antibody-based therapeutics targeting novel immune checkpoints and myeloid cell regulators.

Research and development activities are conducted primarily in Israel, while clinical development, regulatory engagement, and corporate functions support global operations. Compugen controls a suite of proprietary computational platforms and biological databases that underpin its discovery engine. The company has entered into multiple strategic collaborations with global pharmaceutical companies, including partnerships related to specific immune targets and antibody programs.

Strategic Position & Investments

Compugen’s strategy emphasizes the discovery and development of first-in-class immunotherapies based on novel biology rather than incremental improvements to known targets. Growth initiatives focus on advancing internal clinical programs while selectively partnering assets to share development risk and extend financial runway. The company continues to invest heavily in expanding and refining its predictive discovery infrastructure to maintain a competitive edge in target identification.

Notable strategic activities have included long-term collaborations and option-based agreements with major pharmaceutical companies, as well as continued investment in wholly owned clinical-stage assets. Compugen does not operate as a diversified holding company; instead, its investments are concentrated in its internal pipeline and enabling technologies within immuno-oncology and immune regulation.

Geographic Footprint

Compugen is headquartered in Israel, with its principal offices and research facilities located in the Tel Aviv metropolitan area. The company’s core research, discovery, and early development activities are conducted domestically, leveraging Israel’s established life sciences ecosystem.

Internationally, Compugen maintains a presence in the United States, which serves as a key center for clinical development, investor relations, and business development. Its clinical trials, collaborations, and regulatory interactions span North America and Europe, reflecting its global development strategy despite a relatively concentrated physical footprint.

Leadership & Governance

Compugen is led by an executive team with deep expertise in biotechnology, immunology, and drug development, supported by a board with scientific and industry experience. The leadership emphasizes a long-term, science-driven strategy focused on innovation, disciplined capital allocation, and strategic partnerships to maximize the value of its discovery engine.

Key executives include:

• Anat Cohen-Dayag – President and Chief Executive Officer
• Ami Ben-David – Chief Financial Officer
• Dr. Eran Zimran – Chief Scientific Officer
• Dr. Yifat Geffen – Vice President, Research
• Dr. Jonathan Green – Vice President, Clinical Development

The governance framework aligns management incentives with shareholder interests and emphasizes compliance with U.S. public company standards, as reflected in disclosures made through SEC filings and other regulatory reports.